Literature DB >> 18413764

BH3 mimetic ABT-737 potentiates TRAIL-mediated apoptotic signaling by unsequestering Bim and Bak in human pancreatic cancer cells.

Shengbing Huang1, Frank A Sinicrope.   

Abstract

Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) has been shown to induce mitochondrial apoptotic signaling that can be negatively regulated by prosurvival Bcl-2 proteins. ABT-737 is a small-molecule BH3 mimetic that binds to and antagonizes Bcl-2/Bcl-x(L) but not Mcl-1. We show that ABT-737 can synergistically enhance TRAIL-mediated cytotoxicity in human pancreatic cancer cell lines. ABT-737 was shown to enhance TRAIL-induced apoptosis as shown by DNA fragmentation, activation of caspase-8 and Bid, and cleavage of caspase-3 and poly(ADP-ribose) polymerase. A Bax conformational change induced by TRAIL was enhanced by ABT-737. ABT-737 disrupted the interaction of Bak with Bcl-x(L) in both cell lines. Furthermore, ABT-737 untethered the proapoptotic BH3-only protein Bim from its sequestration by Bcl-x(L) or Bcl-2. Bim small hairpin RNA (shRNA) was shown to attenuate caspase-3 cleavage and to reduce the cytotoxic effects of TRAIL plus ABT-737 compared with shRNA control cells. Finally, Mcl-1 shRNA potentiated caspase-3 cleavage by ABT-737 and enhanced its cytotoxic effects. Taken together, ABT-737 augments TRAIL-induced cell killing by unsequestering Bim and Bak and enhancing a Bax conformational change induced by TRAIL. These findings suggest a novel strategy to enhance cross-talk between the extrinsic and intrinsic apoptotic pathways to improve therapeutic efficacy against pancreatic cancer.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18413764      PMCID: PMC2948486          DOI: 10.1158/0008-5472.CAN-07-2508

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  35 in total

1.  Synergy of the protein farnesyltransferase inhibitor SCH66336 and cisplatin in human cancer cell lines.

Authors:  A A Adjei; J N Davis; L M Bruzek; C Erlichman; S H Kaufmann
Journal:  Clin Cancer Res       Date:  2001-05       Impact factor: 12.531

2.  Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation.

Authors:  Shuang Chen; Yun Dai; Hisashi Harada; Paul Dent; Steven Grant
Journal:  Cancer Res       Date:  2007-01-15       Impact factor: 12.701

Review 3.  The Bcl-2 apoptotic switch in cancer development and therapy.

Authors:  J M Adams; S Cory
Journal:  Oncogene       Date:  2007-02-26       Impact factor: 9.867

4.  Structural insights into the degradation of Mcl-1 induced by BH3 domains.

Authors:  Peter E Czabotar; Erinna F Lee; Mark F van Delft; Catherine L Day; Brian J Smith; David C S Huang; W Douglas Fairlie; Mark G Hinds; Peter M Colman
Journal:  Proc Natl Acad Sci U S A       Date:  2007-03-27       Impact factor: 11.205

5.  The BH3-mimetic GX15-070 synergizes with bortezomib in mantle cell lymphoma by enhancing Noxa-mediated activation of Bak.

Authors:  Patricia Pérez-Galán; Gaël Roué; Neus Villamor; Elias Campo; Dolors Colomer
Journal:  Blood       Date:  2007-01-16       Impact factor: 22.113

6.  Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737.

Authors:  Victoria Del Gaizo Moore; Jennifer R Brown; Michael Certo; Tara M Love; Carl D Novina; Anthony Letai
Journal:  J Clin Invest       Date:  2007-01       Impact factor: 14.808

7.  'Seed' analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737.

Authors:  X Lin; S Morgan-Lappe; X Huang; L Li; D M Zakula; L A Vernetti; S W Fesik; Y Shen
Journal:  Oncogene       Date:  2006-12-18       Impact factor: 9.867

8.  Identification of inhibitors of TRAIL-induced death (ITIDs) in the TRAIL-sensitive colon carcinoma cell line SW480 using a genetic approach.

Authors:  T F Burns; W S El-Deiry
Journal:  J Biol Chem       Date:  2001-08-02       Impact factor: 5.157

9.  Bcl-XL protects pancreatic adenocarcinoma cells against CD95- and TRAIL-receptor-mediated apoptosis.

Authors:  S Hinz; A Trauzold; L Boenicke; C Sandberg; S Beckmann; E Bayer; H Walczak; H Kalthoff; H Ungefroren
Journal:  Oncogene       Date:  2000-11-16       Impact factor: 9.867

10.  Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death.

Authors:  M Stacey Ricci; Seok-Hyun Kim; Kazuhiro Ogi; John P Plastaras; Jianhua Ling; Wenge Wang; Zhaoyu Jin; Yingqiu Y Liu; David T Dicker; Paul J Chiao; Keith T Flaherty; Charles D Smith; Wafik S El-Deiry
Journal:  Cancer Cell       Date:  2007-07       Impact factor: 31.743

View more
  66 in total

1.  Synergistic activity of fenretinide and the Bcl-2 family protein inhibitor ABT-737 against human neuroblastoma.

Authors:  Hua Fang; Theresa M Harned; Ondrej Kalous; Vanessa Maldonado; Yves A DeClerck; C Patrick Reynolds
Journal:  Clin Cancer Res       Date:  2011-09-20       Impact factor: 12.531

Review 2.  BH3-only proteins in apoptosis at a glance.

Authors:  Lina Happo; Andreas Strasser; Suzanne Cory
Journal:  J Cell Sci       Date:  2012-03-01       Impact factor: 5.285

3.  Bax/Bak-independent mitochondrial depolarization and reactive oxygen species induction by sorafenib overcome resistance to apoptosis in renal cell carcinoma.

Authors:  Bernhard Gillissen; Anja Richter; Antje Richter; Robert Preissner; Klaus Schulze-Osthoff; Frank Essmann; Peter T Daniel
Journal:  J Biol Chem       Date:  2017-02-01       Impact factor: 5.157

4.  Prognostic impact of bim, puma, and noxa expression in human colon carcinomas.

Authors:  Frank A Sinicrope; Rafaela L Rego; Kenji Okumura; Nathan R Foster; Michael J O'Connell; Daniel J Sargent; Harold E Windschitl
Journal:  Clin Cancer Res       Date:  2008-09-15       Impact factor: 12.531

5.  p62/sequestosome-1 up-regulation promotes ABT-263-induced caspase-8 aggregation/activation on the autophagosome.

Authors:  Shengbing Huang; Koichi Okamoto; Chunrong Yu; Frank A Sinicrope
Journal:  J Biol Chem       Date:  2013-10-11       Impact factor: 5.157

6.  Antagonism of Beclin 1-dependent autophagy by BCL-2 at the endoplasmic reticulum requires NAF-1.

Authors:  Natasha C Chang; Mai Nguyen; Marc Germain; Gordon C Shore
Journal:  EMBO J       Date:  2009-12-10       Impact factor: 11.598

7.  Anti-apoptotic genes in the survival of monocytic cells during infection.

Authors:  Aurelia Busca; Mansi Saxena; Marko Kryworuchko; Ashok Kumar
Journal:  Curr Genomics       Date:  2009-08       Impact factor: 2.236

8.  HDAC2 attenuates TRAIL-induced apoptosis of pancreatic cancer cells.

Authors:  Susanne Schüler; Petra Fritsche; Sandra Diersch; Alexander Arlt; Roland M Schmid; Dieter Saur; Günter Schneider
Journal:  Mol Cancer       Date:  2010-04-16       Impact factor: 27.401

9.  c-FLIP degradation mediates sensitization of pancreatic cancer cells to TRAIL-induced apoptosis by the histone deacetylase inhibitor LBH589.

Authors:  John Kauh; Songqing Fan; Mingjing Xia; Ping Yue; Lily Yang; Fadlo R Khuri; Shi-Yong Sun
Journal:  PLoS One       Date:  2010-04-28       Impact factor: 3.240

10.  Chemical perturbation of Mcl-1 pre-mRNA splicing to induce apoptosis in cancer cells.

Authors:  Yang Gao; Kazunori Koide
Journal:  ACS Chem Biol       Date:  2013-03-13       Impact factor: 5.100

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.